{
  "test_date": "2025-08-01T03:42:49.644Z",
  "model": "z-ai/glm-4.5-air:free",
  "question_id": "gpqa-1",
  "question_category": "Molecular Biology",
  "question_domain": "Biology",
  "prompt_sent": "Question: A large gene has dozens of exons, of which the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space. Each exon usually codes for one folded triple alpha helix. The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Several missing exons are well tolerated by an organism. Which structure below is not involved in the proposed therapy?\n\nOptions:\n\nA) antisense\nB) polyA tail\nC) lariat\nD) R-loops",
  "model_response": "\nI'll analyze this question as a molecular geneticist specializing in RNA therapeutics and splicing mechanisms.\n\n**Dr. Alan Reed, Molecular Geneticist & RNA Therapeutics Specialist**\n\nLet me analyze the proposed therapy and identify which structure is not involved:\n\nThe therapy described uses a Morpholino to target pre-mRNA splicing. Here's how it works:\n1. Morpholinos are antisense molecules (option A) that bind to specific RNA sequences\n2. They bind to the 5' end of the out-of-frame exon in pre-mRNA\n3. This prevents the spliceosome from binding to the pre-mRNA\n4. Without spliceosome binding, exon skipping occurs, resulting in in-frame joining of exons\n5. This approach bypasses the deleterious effects of the mutation\n\nNow let's evaluate each option:\n\nA) Antisense: Morpholinos are indeed antisense molecules that bind to complementary RNA sequences. This is fundamental to the therapy mechanism.\n\nB) PolyA tail: The polyA tail is added to the 3' end of mature mRNA after splicing is complete. The therapy acts at the pre-mRNA level, targeting splicing before polyadenylation occurs. The polyA tail plays no role in spliceosome function or exon skipping.\n\nC) Lariat: During normal splicing, the spliceosome forms a lariat structure when removing introns. By preventing spliceosome binding, the therapy indirectly affects lariat formation. Thus, lariats are involved in the normal splicing process that the therapy interferes with.\n\nD) R-loops: These are three-stranded structures formed by RNA-DNA hybrids. While they can influence gene expression, they're not directly involved in standard pre-mRNA splicing or the described exon-skipping therapy.\n\nThe structure that is definitively not involved in the proposed therapy is the polyA tail (option B). This is because:\n- The therapy targets pre-mRNA splicing\n- Polyadenylation occurs after splicing is complete\n- The polyA tail has no role in spliceosome recognition or function\n\nTherefore, the answer is B) polyA tail.",
  "extracted_answer": "B",
  "correct_answer": "D",
  "is_correct": false,
  "response_time_ms": 19902,
  "search_used": false
}